Last reviewed · How we verify

NCT05387811: GLOBAL-AKI

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Completed Last updated 30 January 2024
What this trial tests

trial testing Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy in Liver Cirrhosis in 1,456 participants. Completed in 30 November 2023.

Timeline
1 July 2022
Primary endpoint
30 September 2023
30 November 2023

Quick facts

Lead sponsorAzienda Ospedaliera di Padova
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,456
Start date1 July 2022
Primary completion30 September 2023
Estimated completion30 November 2023
Sites38 locations across Italy, Paraguay, Poland, South Korea, Denmark, Netherlands, Russia, Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliera di Padova — full company profile →

Who can join

18 and older, any sex, with Liver Cirrhosis or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this study will be to identify the clinical characteristics, the management and the outcomes of acute kidney injury in patients with cirrhosis worldwide. Specific aims: 1. To establish the severity of AKI across different regions 2. To identify precipitants of AKI across different centers 3. To identify the phenotypes of AKI across different centers 4. To evaluate differences in the management of AKI across different centers and their impact on clinical outcomes 5. To assess outcomes of acute kidney injury (resolution of AKI, in-hospital mortality, 28-day mortality, 90-day mortality)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study.
    Patidar KR, Ma AT, Juanola A, Barone A, et al · · 2025 · cited 12× · PMID 40058397 · DOI 10.1016/s2468-1253(25)00006-8
  2. Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.
    Ma AT, Juanola A, Patidar KR, Barone A, et al · · 2026 · cited 1× · PMID 40930302 · DOI 10.1016/j.cgh.2025.08.031

Verify or expand the search:

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other Azienda Ospedaliera di Padova trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05387811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing